Back to top
more

Corcept Therapeutics (CORT)

(Delayed Data from NSDQ)

$33.88 USD

33.88
1,047,351

+0.59 (1.77%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $33.34 -0.54 (-1.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nilanjan Banerjee headshot

Navigate Market Turbulence With These 4 Low-Beta Stocks

by Nilanjan Banerjee

It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Cool Company (CLCO), Corcept Therapeutics (CORT), TXO Partners (TXO), & JOYY (YY) are well-poised to gain.

Zacks.com featured highlights include ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics

by Zacks Equity Research

ADMA Biologics, American Superconductor, biote, Lincoln Educational Services and Corcept Therapeutics have been highlighted in this Screen of The Week article.

Nalak Das headshot

5 Stocks With Recent Price Strength to Tap Wall Street Rally

by Nalak Das

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.

Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product

by Zacks Equity Research

The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.

What Makes Corcept (CORT) a Good Fit for 'Trend Investing'

by Zacks Equity Research

Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Incyte (INCY) Gains 19.6% in Three Months: Here's Why

by Zacks Equity Research

Incyte (INCY) jumped 19.6% in the past three months as investors appreciated the stock grants and buyback plan.

Select Medical (SEM) Expands Rehabilitation Services in Central PA

by Zacks Equity Research

Select Medical (SEM) and UPMC unveil a 20-bed satellite facility of Helen M. Simpson Rehabilitation Hospital in West Shore, thus enhancing specialized inpatient rehabilitation care in Central Pennsylvania.

Novo (NVO) Gets CRL From FDA for Weekly Basal Insulin Icodec

by Zacks Equity Research

Novo's (NVO) efforts to get approval for once-weekly basal insulin icodec in the United States suffer a setback as the FDA issues a CRL.

Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug

by Zacks Equity Research

The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.

Corcept (CORT) Shares Rise 20% in Three Months: Here's Why

by Zacks Equity Research

Corcept's (CORT) pipeline progress has been encouraging with relacorilant currently under evaluation for Cushing's syndrome. The NDA for relacorilant is expected to be filed in the third quarter.

Corcept Therapeutics (CORT) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Is Pacira (PCRX) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Up 24.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

by Zacks Equity Research

Corcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating patients with Cushing's syndrome, meets the primary endpoint in a randomized withdrawal phase.

United Therapeutics (UTHR) Q1 Earnings Top, Tyvaso Drives Sales

by Zacks Equity Research

United Therapeutics' (UTHR) first-quarter 2024 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Corcept (CORT) Q1 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the first quarter of 2024. The company increases revenue guidance for 2024.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Corcept (CORT) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for April 17th

by Zacks Equity Research

BYRN, YMAB, SAND, CORT and ENVB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Corcept (CORT) Completes Enrollment in Ovarian Cancer Study

by Zacks Equity Research

The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.

Why Is Catalyst (CPRX) Down 0.6% Since Last Earnings Report?

by Zacks Equity Research

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?

by Zacks Equity Research

Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Will Corcept (CORT) Bank on Korlym in 2024 Amid Stiff Rivalry?

by Zacks Equity Research

Corcept (CORT) expects its sole marketed drug, Korlym, approved for treating Cushing's syndrome, to generate incremental sales and combat stiff competition.

Why Is United Therapeutics (UTHR) Up 8.9% Since Last Earnings Report?

by Zacks Equity Research

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.